Tracking the SPRO option chain helps you see every strike and expiry on Spero Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Spero Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of SPRO options activity at a glance. Use our scanner to monitor the SPRO option chain in real time and filter for the SPRO options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For SPRO stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the SPRO option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where SPRO stock options are being actively traded and where they are not.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Spero Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen SPRO options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of SPRO stock options — let the full option chain come to you, pre-filtered and ready to trade.
